Ann D. Thor

22.9k citations

209 papers · 18.3k indexed · 5 hit papers · h-index 68

Impact in

Cancer Research top 0.1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways

Papers in

Oncology 110
- HER2/EGFR in Cancer Research 53
- Cancer-related Molecular Pathways 28
Cancer Research 46
- Breast Cancer Treatment Studies 24

Co-authors: Susan M. Edgerton Jeffrey Schlom Dan H. Moore Bolin Liu S M Edgerton Helene S. Smith Daniel F. Hayes Donald A. Berry
Journals: Journal of Clinical Oncology (16 papers)Cancer Research (11 papers)Human Pathology (11 papers)JNCI Journal of the National Cancer Institute (8 papers)Breast Cancer Research and Treatment (8 papers)
Partner nations: United States Canada China

In The Last Decade

Ann D. Thor

201 papers receiving 17.7k citations

Hit Papers

5 papers align trajectories log scale

Revision of the American Joint Committee on Cancer Staging System for Breast Cancer 2002 · 883 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2002 Journal of Clinical Oncology
2000 Archives of Pathology & Laboratory Medicine
1994 New England Journal of Medicine
1994 Science
1992 JNCI Journal of the National Cancer Institute

Peers

Countries citing papers authored by Ann D. Thor

Since Specialization

Citations

This map shows the geographic impact of Ann D. Thor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann D. Thor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann D. Thor more than expected).

Fields of papers citing papers by Ann D. Thor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann D. Thor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann D. Thor. The network helps show where Ann D. Thor may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ann D. Thor, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ann D. Thor Line = papers co-authored together Ann D. Thor links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers Clinical Cancer Research ·Reema S. Wahdan-Alaswad, Susan M. Edgerton, Romain Labaune, Hyunmin Kim, Aik Choon Tan, Jessica Finlay-Schultz, Elizabeth A. Wellberg, Carol A. Sartorius, Britta M. Jacobsen, Bryan R. Haugen, Bolin Liu, Ann D. Thor	2020	10
2	Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo Cancer Prevention Research ·Radwan Ahmed Bouh, Michael C. Rudolph, Elizabeth A. Wellberg, Erin D. Giles, Reema S. Wahdan-Alaswad, Julie A. Houck, Susan M. Edgerton, Ann D. Thor, Pepper Schedin, Steven M. Anderson, Paul S. MacLean	2017	35
3	Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. PubMed ·Hui Lyu, Jingcao Huang, Susan M. Edgerton, Ann D. Thor, Zhimin He, Bolin Liu	2015	10
4	Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial Clinical Cancer Research ·Bryan P. Schneider, Robert J. Gray, Milan Radovich, Fei Shen, Gail H. Vance, Lang Li, Guanglong Jiang, Kathy D. Miller, Julie R. Gralow, Maura N. Dickler, Melody Cobleigh, Edith A. Perez, T. Çiğdem Oğuzoğlu, Kirsten Vang Nielsen, Sven Müller, Ann D. Thor, George W. Sledge, Joseph A. Sparano, Nancy E. Davidson, Sunil Badve	2013	47
5	Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer Breast Cancer Research ·Shuiliang Wang, Jingcao Huang, Hui Lyu, Bo Cai, Xiaoping Yang, Fang Li, Ming Jen Tan, Susan M. Edgerton, Ann D. Thor, Choon‐Kee Lee, Bolin Liu	2013	42
6	Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer Cancer Research ·Erin D. Giles, Elizabeth A. Wellberg, David P. Astling, Steven M. Anderson, Ann D. Thor, Sonali Jindal, Aik Choon Tan, Pepper Schedin, Paul S. MacLean	2012	50
7	Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation Carcinogenesis ·Xiao Yang, Shi‐Yi Yang, Caroline Bassett Lathrop, Bolin Liu, S M Edgerton, P Shtol'ts, L. T. Archer, Ann D. Thor	2010	27
8	Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100 Journal of Clinical Oncology ·Bryan P. Schneider, Μolin Wang, Milan Radovich, George W. Sledge, Sunil Badve, Ann D. Thor, David A. Flockhart, Bradley A. Hancock, Nancy E. Davidson, Julie R. Gralow, Maura N. Dickler, Edith A. Perez, Melody Cobleigh, Tamara Shenkier, Susan M. Edgerton, Kathy D. Miller	2008	487
9	The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis Cancer Research ·Anjali Naresh, Ann D. Thor, Susan M. Edgerton, Kathleen C. Torkko, Rakesh Kumar, Frank E. Jones	2008	54
10	Survival Signaling by Notch1: Mammalian Target of Rapamycin (mTOR)–Dependent Inhibition of p53 Cancer Research ·Sathish Kumar Mungamuri, Xiaohe Yang, Ann D. Thor, Kumaravel Somasundaram	2006	211
11	Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients Journal of Clinical Oncology ·Lynn G. Dressler, Donald A. Berry, Gloria Broadwater, David P. Cowan, Kelly Cox, Stephanie Griffin, K Santoshi, 千葉慧, Debra B. Novotny, Diane L. Persons, Maurice Barcos, I. Craig Henderson, Edison T. Liu, Ann D. Thor, D. R. Budman, Chun-Chieh Tien, Larry Norton, Daniel F. Hayes	2005	82
12	Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients Journal of Clinical Oncology ·Michael P. DiGiovanna, David F. Stern, Susan M. Edgerton, Nafi'ul Ilmi, Dan H. Moore, Ann D. Thor	2005	193
13	Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization–Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial Journal of Clinical Oncology ·Karen L. Tedesco, Ann D. Thor, Douglas H. Johnson, Yu Shyr, Omid Mojarad, Lori J. Goldstein, William J. Gradishar, Brenda P. Nicholson, Douglas E. Merkel, Laura Helie, S. Edgerton, George W. Sledge	2004	83
14	Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198) Breast Cancer Research and Treatment ·G. W. Sledge, A. O’Neill, Ann D. Thor, Stephen P. Kahanic, T. Zelante, Nancy E. Davidson	2001	4
15	Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. PubMed ·Jaime Juárez Ortega, S M Edgerton, Dan H. Moore, Ann D. Thor	2001	101
16	HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer Journal of Clinical Oncology ·Donald A. Berry, Hyman B. Muss, Ann D. Thor, Lynn Dressler, Edison T. Liu, Gloria Broadwater, D. R. Budman, I. Craig Henderson, Maurice Barcos, Daniel F. Hayes, Larry Norton	2000	146
17	HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer Oncogene ·Christopher C. Benz, Rónán C. O’Hagan, B. Diane Richter, Gary K. Scott, Chuan-Hsiung Chang, Xiaohui Xiong, Karen Chew, Britt‐Marie Ljung, Susan M. Edgerton, Ann D. Thor, John A. Hassell	1997	142
18	Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas Science ·Guoren Deng, You Lü, Shengwei Chen, Ann D. Thor, Helene S. Smith	1996	450
19	p53 mutations in benign breast tissue. Journal of Clinical Oncology ·Robert C. Millikan, Barbara S. Hulka, Ann D. Thor, Enas Khamis, S. Edgerton, Marilyn Alkins, Huang Pei, Mei He, Lester E. Wold, L. Joseph Melton	1995	63
20	Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. PubMed ·Ann D. Thor, Laurent H. Schwartz, Frederick C. Koerner, S M Edgerton, Steven J. Skates, Lena Bader, Robert A. Ostroski, Dennis Panicali, Yingying Xu, Howard Fingert	1989	104

About Ann D. Thor

Ann D. Thor is a scholar working on Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, Immunology and Allergy and Molecular Biology, having authored 209 papers that have together received 18.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (53 papers), Monoclonal and Polyclonal Antibodies Research (53 papers), Cancer-related Molecular Pathways (28 papers), Breast Cancer Treatment Studies (24 papers), Glycosylation and Glycoproteins Research (22 papers), Metabolism, Diabetes, and Cancer (17 papers), Radiopharmaceutical Chemistry and Applications (16 papers) and Breast Lesions and Carcinomas (13 papers). The work is most often cited by research in Cancer Research (5.8k citations), Oncology (9.7k citations), Radiology, Nuclear Medicine and Imaging (3.4k citations), Pathology and Forensic Medicine (2.4k citations) and Molecular Biology (8.3k citations). Ann D. Thor has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Susan M. Edgerton, Jeffrey Schlom, Dan H. Moore, Bolin Liu, S M Edgerton, Helene S. Smith, Daniel F. Hayes, Donald A. Berry, Zeying Fan and Cheryl A. Szpak. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Human Pathology, JNCI Journal of the National Cancer Institute and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact